Provided herein are compounds of formula (V) that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease.
-
Page/Page column 40; 145
(2022/02/05)
Inhibitory phosphodiesterase 4-contained compound and preparation and medical application methods thereof
The invention relates to the field of medicinal chemistry, particularly to an inhibitory phosphodiesterase 4-contained micro-molecular compound (I), a preparation method of the inhibitory phosphodiesterase 4-contained micro-molecular compound (I) and a pharmaceutical composition containing the inhibitory phosphodiesterase 4-contained micro-molecular compound (I). pharmacodynamics experiments provethat the inhibitory phosphodiesterase 4-contained micro-molecular compound (I) achieves the activity inhibiting and inflammation treating effects of PDE-4 (phosphodiesterase 4).
-
Paragraph 0051; 0053; 0054; 0055
(2018/07/15)
BENZOTHIOPHENE DERIVATIVE
[Problem to be Solved] It is intended to provide a compound having PDE10A inhibitory activity and having a novel structure, or an isotope thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. [Solution] The present invention provides a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof.
-
(2016/02/18)
COMPOSITIONS AND METHODS FOR MODULATING FXR
The present invention relates to compounds of Formula (I), a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesiod X receptors (FXR).
-
Page/Page column 118
(2012/07/13)
QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS
The present invention is related to novel compounds of formula (I) having P2X7 antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans. (I)
-
Page/Page column 22
(2009/12/05)
More Articles about upstream products of 1192569-38-2